initialization_att1r_project

Quarto

Positive vs non-positive

Characteristic	Overall N = 491	negative and at risk N = 371	positive N = 121	p-value2
Age at time of sample (years)	75 (67, 80)	74 (68, 79)	76 (66, 81)	0.8
Female sex	23 (47%)	17 (46%)	6 (50%)	0.8
Race				0.5
asian	1 (2.0%)	1 (2.7%)	0 (0%)
black/aa	6 (12%)	6 (16%)	0 (0%)
white	42 (86%)	30 (81%)	12 (100%)
Ethnicity				0.2
hispanic/latinx	1 (2.0%)	0 (0%)	1 (8.3%)
not hispanic/latinx	48 (98%)	37 (100%)	11 (92%)
Number of immune-related adverse events (iRAEs)	2 (1, 3)	2 (1, 3)	3 (1, 4)	0.6
AT1R antibody interpretation				<0.001
at risk	15 (31%)	15 (41%)	0 (0%)
negative	22 (45%)	22 (59%)	0 (0%)
positive	12 (24%)	0 (0%)	12 (100%)
Death	19 (40%)	13 (36%)	6 (50%)	0.5
Heart failure at baseline	8 (16%)	5 (14%)	3 (25%)	0.4
Heart failure at outcome				>0.9
0	32 (65%)	24 (65%)	8 (67%)
1	16 (33%)	12 (32%)	4 (33%)
1 (recovered then HFrEF after ICI)	1 (2.0%)	1 (2.7%)	0 (0%)
Arrhythmia at baseline				>0.9
0	32 (65%)	24 (65%)	8 (67%)
1	17 (35%)	13 (35%)	4 (33%)
Arrhythmia at outcome				0.5
0	29 (59%)	23 (62%)	6 (50%)
1	20 (41%)	14 (38%)	6 (50%)
New arrhythmia	16 (33%)	11 (30%)	5 (42%)	0.5
ACE inhibitor or ARB use				0.044
0	31 (63%)	20 (54%)	11 (92%)
0 on admission, started lisinopril 3/17/2022	1 (2.0%)	1 (2.7%)	0 (0%)
1	17 (35%)	16 (43%)	1 (8.3%)
Spironolactone (aldactone) use	1 (2.0%)	1 (2.7%)	0 (0%)	>0.9
SGLT2 inhibitor use	2 (4.1%)	2 (5.4%)	0 (0%)	>0.9
Beta-blocker use				0.7
0	26 (53%)	18 (49%)	8 (67%)
1	21 (43%)	17 (46%)	4 (33%)
1 (atenolol)	1 (2.0%)	1 (2.7%)	0 (0%)
1 (nadolol)	1 (2.0%)	1 (2.7%)	0 (0%)
myocarditis_severty_adjudication				>0.9
1	3 (6.1%)	2 (5.4%)	1 (8.3%)
1 (asx)	1 (2.0%)	1 (2.7%)	0 (0%)
1 (hypotension but likely 2/2 to other conditions)	1 (2.0%)	0 (0%)	1 (8.3%)
2	4 (8.2%)	3 (8.1%)	1 (8.3%)
2 (cardiac MRI with signs of prior myocarditis but not active)	1 (2.0%)	1 (2.7%)	0 (0%)
2 (could be 1, had mild dyspnea likely attribuate to concurrent irae pneumonitis)	1 (2.0%)	1 (2.7%)	0 (0%)
2 (had cMRI that does not seem conclusive for myocarditis, had CP)	1 (2.0%)	1 (2.7%)	0 (0%)
2 (Had CP but likely due to pericardial effusion)	1 (2.0%)	1 (2.7%)	0 (0%)
2 (mildly reduced EF but no clear sx)	1 (2.0%)	1 (2.7%)	0 (0%)
2 (normal echo, ? cardiogenic syncope)	1 (2.0%)	0 (0%)	1 (8.3%)
2 (unstable but for other reasons)	1 (2.0%)	1 (2.7%)	0 (0%)
2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent)	1 (2.0%)	1 (2.7%)	0 (0%)
3	18 (37%)	12 (32%)	6 (50%)
3 (based on MRI)	1 (2.0%)	1 (2.7%)	0 (0%)
3 (cMRI 11/2022 with myocarditis)	1 (2.0%)	1 (2.7%)	0 (0%)
3 (cMRI suggestive and TTE with known apical akinesis iso scar)	1 (2.0%)	1 (2.7%)	0 (0%)
3 (EF 25 - 30% w/ sx but no instability)	1 (2.0%)	1 (2.7%)	0 (0%)
3 (EF drop w/ CP but no instability)	1 (2.0%)	1 (2.7%)	0 (0%)
3 (In MICU but for AHRF 2/2 lung dz)	1 (2.0%)	1 (2.7%)	0 (0%)
3 (MRI read equivocal but seems real enough)	1 (2.0%)	1 (2.7%)	0 (0%)
4	6 (12%)	4 (11%)	2 (17%)
4 (aggressively worsening trops despite immunosupp, hypotension likely iso sepsis but seems like grade 4)	1 (2.0%)	1 (2.7%)	0 (0%)
Prolonged immunosuppression	29 (63%)	19 (53%)	10 (100%)	0.008
Number of non-HLA positive beads	4.0 (1.0, 12.0)	4.0 (1.0, 9.0)	14.5 (6.5, 22.5)	0.10
Metastatic cancer	12 (71%)	9 (69%)	3 (75%)	>0.9
Hypertension	46 (94%)	35 (95%)	11 (92%)	>0.9
Hyperlipidemia	39 (80%)	29 (78%)	10 (83%)	>0.9
Coronary artery disease	31 (63%)	22 (59%)	9 (75%)	0.5
Diabetes mellitus	12 (24%)	10 (27%)	2 (17%)	0.7
Heart failure	17 (35%)	11 (30%)	6 (50%)	0.3
Valvular disease	2 (4.1%)	1 (2.7%)	1 (8.3%)	0.4
Ipilimumab (IPI)	13 (27%)	8 (22%)	5 (42%)	0.3
Nivolumab (NIVO)	19 (39%)	14 (38%)	5 (42%)	>0.9
Pembrolizumab (PEMBRO)	24 (49%)	17 (46%)	7 (58%)	0.5
Durvalumab (DURVA)	5 (10%)	3 (8.1%)	2 (17%)	0.6
Atezolizumab (ATEZO)	3 (6.1%)	3 (8.1%)	0 (0%)	0.6
Days from initial ICI exposure to presentation	57 (34, 264)	57 (35, 229)	78 (30, 805)	0.6
Pulse-dose steroids given	47 (96%)	36 (97%)	11 (92%)	0.4
Prolonged steroid course after pulse	25 (51%)	18 (49%)	7 (58%)	0.6
Mycophenolate mofetil (MMF)	31 (63%)	22 (59%)	9 (75%)	0.5
Abatacept	19 (39%)	13 (35%)	6 (50%)	0.5
IVIG	12 (24%)	7 (19%)	5 (42%)	0.14
Infliximab	2 (4.1%)	1 (2.7%)	1 (8.3%)	0.4
Tofacitinib	15 (31%)	12 (32%)	3 (25%)	0.7
Any immunosuppression escalation	28 (57%)	18 (49%)	10 (83%)	0.035
Number of immunosuppression escalations	1.00 (0.00, 1.00)	1.00 (0.00, 1.00)	1.00 (1.00, 1.50)	0.074
LVEF (%) — clinical	54 (43, 61)	53 (39, 58)	58 (58, 64)	0.14
RVEF (%) — clinical	49 (43, 52)	49 (40, 51)	50 (45, 58)	0.3
Cardiomyopathy etiology				0.6
	10 (23%)	7 (21%)	3 (27%)
0	1 (2.3%)	1 (3.0%)	0 (0%)
both	4 (9.1%)	3 (9.1%)	1 (9.1%)
ischemic	1 (2.3%)	1 (3.0%)	0 (0%)
ischemic_nonischemic_both_sheet_4	3 (6.8%)	1 (3.0%)	2 (18%)
nonischemic	25 (57%)	20 (61%)	5 (45%)
Other irAEs				0.4
	47 (96%)	36 (97%)	11 (92%)
myositis, MG myocarditis	1 (2.0%)	0 (0%)	1 (8.3%)
pneumonitis	1 (2.0%)	1 (2.7%)	0 (0%)
Native T1, CMR (ms)	992 (964, 1,016)	1,015 (973, 1,024)	965 (938, 1,012)	0.14
ECV, CMR (%) — categories	30.0 (26.0, 35.0)	30.0 (26.0, 34.0)	31.0 (24.5, 38.0)	0.6
T2 (0=normal, 1=elevated)	19 (53%)	13 (50%)	6 (60%)	0.7
LGE burden, CMR (% LV mass)	8 (3, 14)	7 (0, 10)	13 (4, 40)	0.033
CM outcome (1 = event)	16 (89%)	14 (93%)	2 (67%)	0.3
LVEF, CMR (%)	59 (47, 64)	58 (44, 62)	62 (58, 66)	0.14
RVEF, CMR (%)	52 (47, 55)	51 (47, 54)	53 (48, 58)	0.2
LV wall thickness (AP), mm	10.00 (8.00, 11.00)	10.00 (8.00, 11.00)	10.00 (6.50, 11.50)	0.7
LV wall thickness (PL), mm	8.00 (7.00, 10.00)	8.00 (7.00, 9.00)	9.00 (7.00, 10.50)	0.2
Global radial strain, CMR (%)	26 (20, 35)	23 (20, 31)	35 (24, 37)	0.062
Global circumferential strain, CMR (%)	-16.0 (-19.6, -13.6)	-15.1 (-18.1, -13.0)	-18.8 (-20.2, -15.3)	0.077
Global longitudinal strain (GLS), CMR (%)	-13.3 (-16.1, -9.6)	-12.5 (-15.2, -9.1)	-15.3 (-17.6, -10.8)	0.2
Abnormal GLS	35 (85%)	27 (90%)	8 (73%)	0.3
MAPSE — anterior (mm)	9.7 (6.3, 12.4)	9.7 (5.9, 12.4)	10.2 (7.3, 12.2)	0.7
MAPSE — inferior (mm)	11.2 (9.5, 14.5)	11.7 (8.9, 14.6)	10.8 (9.8, 13.3)	0.8
MAPSE — mean (mm)	10.2 (7.8, 12.5)	10.2 (7.1, 12.8)	11.3 (8.7, 12.3)	0.8
remove_variavle
1	1 (100%)	1 (100%)	0 (NA%)
at1r_bracket_num	11 (7, 17)	9 (7, 12)	22 (20, 33)	<0.001
myocarditis_severity_num				0.8
1	5 (10%)	3 (8.1%)	2 (17%)
2	12 (24%)	10 (27%)	2 (17%)
3	25 (51%)	19 (51%)	6 (50%)
4	7 (14%)	5 (14%)	2 (17%)
1 Median (Q1, Q3); n (%)
2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA

Negative vs non-negative

Characteristic	Overall N = 491	negative N = 221	positive and at risk N = 271	p-value2
Age at time of sample (years)	75 (67, 80)	75 (68, 80)	75 (65, 78)	0.6
Female sex	23 (47%)	10 (45%)	13 (48%)	0.9
Race				0.3
asian	1 (2.0%)	1 (4.5%)	0 (0%)
black/aa	6 (12%)	4 (18%)	2 (7.4%)
white	42 (86%)	17 (77%)	25 (93%)
Ethnicity				>0.9
hispanic/latinx	1 (2.0%)	0 (0%)	1 (3.7%)
not hispanic/latinx	48 (98%)	22 (100%)	26 (96%)
Number of immune-related adverse events (iRAEs)	2 (1, 3)	2 (1, 3)	2 (1, 4)	0.2
AT1R antibody interpretation				<0.001
at risk	15 (31%)	0 (0%)	15 (56%)
negative	22 (45%)	22 (100%)	0 (0%)
positive	12 (24%)	0 (0%)	12 (44%)
Death	19 (40%)	7 (32%)	12 (46%)	0.3
Heart failure at baseline	8 (16%)	3 (14%)	5 (19%)	0.7
Heart failure at outcome				>0.9
0	32 (65%)	15 (68%)	17 (63%)
1	16 (33%)	7 (32%)	9 (33%)
1 (recovered then HFrEF after ICI)	1 (2.0%)	0 (0%)	1 (3.7%)
Arrhythmia at baseline				0.7
0	32 (65%)	15 (68%)	17 (63%)
1	17 (35%)	7 (32%)	10 (37%)
Arrhythmia at outcome				0.2
0	29 (59%)	15 (68%)	14 (52%)
1	20 (41%)	7 (32%)	13 (48%)
New arrhythmia	16 (33%)	6 (27%)	10 (37%)	0.5
ACE inhibitor or ARB use				0.6
0	31 (63%)	13 (59%)	18 (67%)
0 on admission, started lisinopril 3/17/2022	1 (2.0%)	1 (4.5%)	0 (0%)
1	17 (35%)	8 (36%)	9 (33%)
Spironolactone (aldactone) use	1 (2.0%)	0 (0%)	1 (3.7%)	>0.9
SGLT2 inhibitor use	2 (4.1%)	2 (9.1%)	0 (0%)	0.2
Beta-blocker use				0.6
0	26 (53%)	11 (50%)	15 (56%)
1	21 (43%)	9 (41%)	12 (44%)
1 (atenolol)	1 (2.0%)	1 (4.5%)	0 (0%)
1 (nadolol)	1 (2.0%)	1 (4.5%)	0 (0%)
myocarditis_severty_adjudication				0.6
1	3 (6.1%)	2 (9.1%)	1 (3.7%)
1 (asx)	1 (2.0%)	1 (4.5%)	0 (0%)
1 (hypotension but likely 2/2 to other conditions)	1 (2.0%)	0 (0%)	1 (3.7%)
2	4 (8.2%)	3 (14%)	1 (3.7%)
2 (cardiac MRI with signs of prior myocarditis but not active)	1 (2.0%)	1 (4.5%)	0 (0%)
2 (could be 1, had mild dyspnea likely attribuate to concurrent irae pneumonitis)	1 (2.0%)	1 (4.5%)	0 (0%)
2 (had cMRI that does not seem conclusive for myocarditis, had CP)	1 (2.0%)	0 (0%)	1 (3.7%)
2 (Had CP but likely due to pericardial effusion)	1 (2.0%)	0 (0%)	1 (3.7%)
2 (mildly reduced EF but no clear sx)	1 (2.0%)	0 (0%)	1 (3.7%)
2 (normal echo, ? cardiogenic syncope)	1 (2.0%)	0 (0%)	1 (3.7%)
2 (unstable but for other reasons)	1 (2.0%)	0 (0%)	1 (3.7%)
2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent)	1 (2.0%)	1 (4.5%)	0 (0%)
3	18 (37%)	7 (32%)	11 (41%)
3 (based on MRI)	1 (2.0%)	0 (0%)	1 (3.7%)
3 (cMRI 11/2022 with myocarditis)	1 (2.0%)	0 (0%)	1 (3.7%)
3 (cMRI suggestive and TTE with known apical akinesis iso scar)	1 (2.0%)	1 (4.5%)	0 (0%)
3 (EF 25 - 30% w/ sx but no instability)	1 (2.0%)	1 (4.5%)	0 (0%)
3 (EF drop w/ CP but no instability)	1 (2.0%)	0 (0%)	1 (3.7%)
3 (In MICU but for AHRF 2/2 lung dz)	1 (2.0%)	0 (0%)	1 (3.7%)
3 (MRI read equivocal but seems real enough)	1 (2.0%)	1 (4.5%)	0 (0%)
4	6 (12%)	3 (14%)	3 (11%)
4 (aggressively worsening trops despite immunosupp, hypotension likely iso sepsis but seems like grade 4)	1 (2.0%)	0 (0%)	1 (3.7%)
Prolonged immunosuppression	29 (63%)	11 (52%)	18 (72%)	0.2
Number of non-HLA positive beads	4.0 (1.0, 12.0)	1.0 (1.0, 1.0)	6.5 (3.0, 14.0)	0.030
Metastatic cancer	12 (71%)	6 (60%)	6 (86%)	0.3
Hypertension	46 (94%)	21 (95%)	25 (93%)	>0.9
Hyperlipidemia	39 (80%)	17 (77%)	22 (81%)	0.7
Coronary artery disease	31 (63%)	15 (68%)	16 (59%)	0.5
Diabetes mellitus	12 (24%)	6 (27%)	6 (22%)	0.7
Heart failure	17 (35%)	5 (23%)	12 (44%)	0.11
Valvular disease	2 (4.1%)	1 (4.5%)	1 (3.7%)	>0.9
Ipilimumab (IPI)	13 (27%)	4 (18%)	9 (33%)	0.2
Nivolumab (NIVO)	19 (39%)	8 (36%)	11 (41%)	0.8
Pembrolizumab (PEMBRO)	24 (49%)	10 (45%)	14 (52%)	0.7
Durvalumab (DURVA)	5 (10%)	2 (9.1%)	3 (11%)	>0.9
Atezolizumab (ATEZO)	3 (6.1%)	1 (4.5%)	2 (7.4%)	>0.9
Days from initial ICI exposure to presentation	57 (34, 264)	56 (42, 145)	66 (31, 276)	0.8
Pulse-dose steroids given	47 (96%)	21 (95%)	26 (96%)	>0.9
Prolonged steroid course after pulse	25 (51%)	13 (59%)	12 (44%)	0.3
Mycophenolate mofetil (MMF)	31 (63%)	15 (68%)	16 (59%)	0.5
Abatacept	19 (39%)	9 (41%)	10 (37%)	0.8
IVIG	12 (24%)	5 (23%)	7 (26%)	0.8
Infliximab	2 (4.1%)	1 (4.5%)	1 (3.7%)	>0.9
Tofacitinib	15 (31%)	8 (36%)	7 (26%)	0.4
Any immunosuppression escalation	28 (57%)	10 (45%)	18 (67%)	0.14
Number of immunosuppression escalations	1.00 (0.00, 1.00)	0.50 (0.00, 1.00)	1.00 (0.00, 1.00)	0.3
LVEF (%) — clinical	54 (43, 61)	54 (41, 59)	55 (43, 64)	0.7
RVEF (%) — clinical	49 (43, 52)	46 (39, 50)	49 (45, 56)	0.2
Cardiomyopathy etiology				0.2
	10 (23%)	6 (30%)	4 (17%)
0	1 (2.3%)	1 (5.0%)	0 (0%)
both	4 (9.1%)	0 (0%)	4 (17%)
ischemic	1 (2.3%)	1 (5.0%)	0 (0%)
ischemic_nonischemic_both_sheet_4	3 (6.8%)	1 (5.0%)	2 (8.3%)
nonischemic	25 (57%)	11 (55%)	14 (58%)
Other irAEs				0.7
	47 (96%)	21 (95%)	26 (96%)
myositis, MG myocarditis	1 (2.0%)	0 (0%)	1 (3.7%)
pneumonitis	1 (2.0%)	1 (4.5%)	0 (0%)
Native T1, CMR (ms)	992 (964, 1,016)	1,004 (982, 1,020)	977 (953, 1,015)	0.4
ECV, CMR (%) — categories	30.0 (26.0, 35.0)	28.5 (26.0, 35.0)	31.0 (23.0, 36.0)	0.8
T2 (0=normal, 1=elevated)	19 (53%)	8 (44%)	11 (61%)	0.3
LGE burden, CMR (% LV mass)	8 (3, 14)	6 (0, 10)	10 (4, 20)	0.037
CM outcome (1 = event)	16 (89%)	7 (88%)	9 (90%)	>0.9
LVEF, CMR (%)	59 (47, 64)	60 (53, 62)	58 (47, 64)	>0.9
RVEF, CMR (%)	52 (47, 55)	52 (49, 54)	50 (42, 58)	0.8
LV wall thickness (AP), mm	10.00 (8.00, 11.00)	10.00 (8.00, 11.00)	11.00 (9.00, 12.00)	0.2
LV wall thickness (PL), mm	8.00 (7.00, 10.00)	8.00 (6.00, 9.00)	9.00 (7.00, 10.00)	0.2
Global radial strain, CMR (%)	26 (20, 35)	28 (20, 31)	24 (20, 36)	0.6
Global circumferential strain, CMR (%)	-16.0 (-19.6, -13.6)	-17.8 (-18.3, -13.0)	-15.2 (-19.8, -13.6)	>0.9
Global longitudinal strain (GLS), CMR (%)	-13.3 (-16.1, -9.6)	-14.0 (-16.7, -11.9)	-11.2 (-15.3, -9.1)	0.2
Abnormal GLS	35 (85%)	16 (89%)	19 (83%)	0.7
MAPSE — anterior (mm)	9.7 (6.3, 12.4)	10.4 (6.1, 14.7)	9.3 (7.2, 11.7)	0.2
MAPSE — inferior (mm)	11.2 (9.5, 14.5)	13.0 (10.0, 14.6)	10.6 (8.9, 13.3)	0.3
MAPSE — mean (mm)	10.2 (7.8, 12.5)	11.6 (7.1, 13.6)	10.0 (8.0, 12.0)	0.4
remove_variavle
1	1 (100%)	1 (100%)	0 (NA%)
at1r_bracket_num	11 (7, 17)	7 (6, 9)	15 (12, 22)	<0.001
myocarditis_severity_num				0.9
1	5 (10%)	3 (14%)	2 (7.4%)
2	12 (24%)	6 (27%)	6 (22%)
3	25 (51%)	10 (45%)	15 (56%)
4	7 (14%)	3 (14%)	4 (15%)
1 Median (Q1, Q3); n (%)
2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA

Removed all “at risk”

Characteristic	Overall N = 341	negative N = 221	positive N = 121	p-value2
Age at time of sample (years)	75 (68, 80)	75 (68, 80)	76 (66, 81)	>0.9
Female sex	16 (47%)	10 (45%)	6 (50%)	0.8
Race				0.3
asian	1 (2.9%)	1 (4.5%)	0 (0%)
black/aa	4 (12%)	4 (18%)	0 (0%)
white	29 (85%)	17 (77%)	12 (100%)
Ethnicity				0.4
hispanic/latinx	1 (2.9%)	0 (0%)	1 (8.3%)
not hispanic/latinx	33 (97%)	22 (100%)	11 (92%)
Number of immune-related adverse events (iRAEs)	2 (1, 3)	2 (1, 3)	3 (1, 4)	0.4
AT1R antibody interpretation				<0.001
negative	22 (65%)	22 (100%)	0 (0%)
positive	12 (35%)	0 (0%)	12 (100%)
Death	13 (38%)	7 (32%)	6 (50%)	0.5
Heart failure at baseline	6 (18%)	3 (14%)	3 (25%)	0.6
Heart failure at outcome				>0.9
0	23 (68%)	15 (68%)	8 (67%)
1	11 (32%)	7 (32%)	4 (33%)
Arrhythmia at baseline				>0.9
0	23 (68%)	15 (68%)	8 (67%)
1	11 (32%)	7 (32%)	4 (33%)
Arrhythmia at outcome				0.5
0	21 (62%)	15 (68%)	6 (50%)
1	13 (38%)	7 (32%)	6 (50%)
New arrhythmia	11 (32%)	6 (27%)	5 (42%)	0.5
ACE inhibitor or ARB use				0.14
0	24 (71%)	13 (59%)	11 (92%)
0 on admission, started lisinopril 3/17/2022	1 (2.9%)	1 (4.5%)	0 (0%)
1	9 (26%)	8 (36%)	1 (8.3%)
Spironolactone (aldactone) use
0	34 (100%)	22 (100%)	12 (100%)
SGLT2 inhibitor use	2 (5.9%)	2 (9.1%)	0 (0%)	0.5
Beta-blocker use				0.9
0	19 (56%)	11 (50%)	8 (67%)
1	13 (38%)	9 (41%)	4 (33%)
1 (atenolol)	1 (2.9%)	1 (4.5%)	0 (0%)
1 (nadolol)	1 (2.9%)	1 (4.5%)	0 (0%)
myocarditis_severty_adjudication				>0.9
1	3 (8.8%)	2 (9.1%)	1 (8.3%)
1 (asx)	1 (2.9%)	1 (4.5%)	0 (0%)
1 (hypotension but likely 2/2 to other conditions)	1 (2.9%)	0 (0%)	1 (8.3%)
2	4 (12%)	3 (14%)	1 (8.3%)
2 (cardiac MRI with signs of prior myocarditis but not active)	1 (2.9%)	1 (4.5%)	0 (0%)
2 (could be 1, had mild dyspnea likely attribuate to concurrent irae pneumonitis)	1 (2.9%)	1 (4.5%)	0 (0%)
2 (normal echo, ? cardiogenic syncope)	1 (2.9%)	0 (0%)	1 (8.3%)
2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent)	1 (2.9%)	1 (4.5%)	0 (0%)
3	13 (38%)	7 (32%)	6 (50%)
3 (cMRI suggestive and TTE with known apical akinesis iso scar)	1 (2.9%)	1 (4.5%)	0 (0%)
3 (EF 25 - 30% w/ sx but no instability)	1 (2.9%)	1 (4.5%)	0 (0%)
3 (MRI read equivocal but seems real enough)	1 (2.9%)	1 (4.5%)	0 (0%)
4	5 (15%)	3 (14%)	2 (17%)
Prolonged immunosuppression	21 (68%)	11 (52%)	10 (100%)	0.012
Number of non-HLA positive beads	1 (1, 12)	1 (1, 1)	15 (7, 23)	0.073
Metastatic cancer	9 (64%)	6 (60%)	3 (75%)	>0.9
Hypertension	32 (94%)	21 (95%)	11 (92%)	>0.9
Hyperlipidemia	27 (79%)	17 (77%)	10 (83%)	>0.9
Coronary artery disease	24 (71%)	15 (68%)	9 (75%)	>0.9
Diabetes mellitus	8 (24%)	6 (27%)	2 (17%)	0.7
Heart failure	11 (32%)	5 (23%)	6 (50%)	0.14
Valvular disease	2 (5.9%)	1 (4.5%)	1 (8.3%)	>0.9
Ipilimumab (IPI)	9 (26%)	4 (18%)	5 (42%)	0.2
Nivolumab (NIVO)	13 (38%)	8 (36%)	5 (42%)	>0.9
Pembrolizumab (PEMBRO)	17 (50%)	10 (45%)	7 (58%)	0.5
Durvalumab (DURVA)	4 (12%)	2 (9.1%)	2 (17%)	0.6
Atezolizumab (ATEZO)	1 (2.9%)	1 (4.5%)	0 (0%)	>0.9
Days from initial ICI exposure to presentation	57 (37, 234)	56 (42, 145)	78 (30, 805)	0.7
Pulse-dose steroids given	32 (94%)	21 (95%)	11 (92%)	>0.9
Prolonged steroid course after pulse	20 (59%)	13 (59%)	7 (58%)	>0.9
Mycophenolate mofetil (MMF)	24 (71%)	15 (68%)	9 (75%)	>0.9
Abatacept	15 (44%)	9 (41%)	6 (50%)	0.6
IVIG	10 (29%)	5 (23%)	5 (42%)	0.3
Infliximab	2 (5.9%)	1 (4.5%)	1 (8.3%)	>0.9
Tofacitinib	11 (32%)	8 (36%)	3 (25%)	0.7
Any immunosuppression escalation	20 (59%)	10 (45%)	10 (83%)	0.066
Number of immunosuppression escalations	1.00 (0.00, 1.00)	0.50 (0.00, 1.00)	1.00 (1.00, 1.50)	0.10
LVEF (%) — clinical	57 (53, 61)	54 (41, 59)	58 (58, 64)	0.2
RVEF (%) — clinical	47 (43, 50)	46 (39, 50)	50 (45, 58)	0.2
Cardiomyopathy etiology				0.6
	9 (29%)	6 (30%)	3 (27%)
0	1 (3.2%)	1 (5.0%)	0 (0%)
both	1 (3.2%)	0 (0%)	1 (9.1%)
ischemic	1 (3.2%)	1 (5.0%)	0 (0%)
ischemic_nonischemic_both_sheet_4	3 (9.7%)	1 (5.0%)	2 (18%)
nonischemic	16 (52%)	11 (55%)	5 (45%)
Other irAEs				0.6
	32 (94%)	21 (95%)	11 (92%)
myositis, MG myocarditis	1 (2.9%)	0 (0%)	1 (8.3%)
pneumonitis	1 (2.9%)	1 (4.5%)	0 (0%)
Native T1, CMR (ms)	992 (957, 1,016)	1,004 (982, 1,020)	965 (938, 1,012)	0.2
ECV, CMR (%) — categories	28.5 (26.0, 36.0)	28.5 (26.0, 35.0)	31.0 (24.5, 38.0)	0.7
T2 (0=normal, 1=elevated)	14 (50%)	8 (44%)	6 (60%)	0.7
LGE burden, CMR (% LV mass)	8 (0, 14)	6 (0, 10)	13 (4, 40)	0.021
CM outcome (1 = event)	9 (82%)	7 (88%)	2 (67%)	0.5
LVEF, CMR (%)	60 (54, 64)	60 (53, 62)	62 (58, 66)	0.3
RVEF, CMR (%)	52 (49, 55)	52 (49, 54)	53 (48, 58)	0.5
LV wall thickness (AP), mm	10.00 (8.00, 11.00)	10.00 (8.00, 11.00)	10.00 (6.50, 11.50)	0.9
LV wall thickness (PL), mm	9.00 (7.00, 9.00)	8.00 (6.00, 9.00)	9.00 (7.00, 10.50)	0.12
Global radial strain, CMR (%)	29 (22, 36)	28 (20, 31)	35 (24, 37)	0.13
Global circumferential strain, CMR (%)	-18.0 (-19.8, -14.8)	-17.8 (-18.3, -13.0)	-18.8 (-20.2, -15.3)	0.2
Global longitudinal strain (GLS), CMR (%)	-14.8 (-17.2, -11.6)	-14.0 (-16.7, -11.9)	-15.3 (-17.6, -10.8)	0.6
Abnormal GLS	24 (83%)	16 (89%)	8 (73%)	0.3
MAPSE — anterior (mm)	10.3 (7.3, 13.4)	10.4 (6.1, 14.7)	10.2 (7.3, 12.2)	0.8
MAPSE — inferior (mm)	12.3 (9.9, 14.5)	13.0 (10.0, 14.6)	10.8 (9.8, 13.3)	0.4
MAPSE — mean (mm)	11.3 (8.6, 12.8)	11.6 (7.1, 13.6)	11.3 (8.7, 12.3)	0.8
remove_variavle
1	1 (100%)	1 (100%)	0 (NA%)
at1r_bracket_num	9 (6, 20)	7 (6, 9)	22 (20, 33)	<0.001
myocarditis_severity_num				>0.9
1	5 (15%)	3 (14%)	2 (17%)
2	8 (24%)	6 (27%)	2 (17%)
3	16 (47%)	10 (45%)	6 (50%)
4	5 (15%)	3 (14%)	2 (17%)
1 Median (Q1, Q3); n (%)
2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA; Wilcoxon rank sum exact test

Clean table for abstract

Characteristic	Overall N = 341	negative N = 221	positive N = 121	p-value2
Age at time of sample (years)	75 (68, 80)	75 (68, 80)	76 (66, 81)	>0.9
Female sex	16 (47%)	10 (45%)	6 (50%)	0.8
Race				0.3
asian	1 (2.9%)	1 (4.5%)	0 (0%)
black/aa	4 (12%)	4 (18%)	0 (0%)
white	29 (85%)	17 (77%)	12 (100%)
Ethnicity				0.4
hispanic/latinx	1 (2.9%)	0 (0%)	1 (8.3%)
not hispanic/latinx	33 (97%)	22 (100%)	11 (92%)
Death	13 (38%)	7 (32%)	6 (50%)	0.5
Prolonged immunosuppression	21 (68%)	11 (52%)	10 (100%)	0.012
Number of non-HLA positive beads	1 (1, 12)	1 (1, 1)	15 (7, 23)	0.073
Hypertension	32 (94%)	21 (95%)	11 (92%)	>0.9
Hyperlipidemia	27 (79%)	17 (77%)	10 (83%)	>0.9
Coronary artery disease	24 (71%)	15 (68%)	9 (75%)	>0.9
Diabetes mellitus	8 (24%)	6 (27%)	2 (17%)	0.7
Heart failure	11 (32%)	5 (23%)	6 (50%)	0.14
LGE burden, CMR (% LV mass)	8 (0, 14)	6 (0, 10)	13 (4, 40)	0.021
LVEF, CMR (%)	60 (54, 64)	60 (53, 62)	62 (58, 66)	0.3
RVEF, CMR (%)	52 (49, 55)	52 (49, 54)	53 (48, 58)	0.5
LV wall thickness (AP), mm	10.00 (8.00, 11.00)	10.00 (8.00, 11.00)	10.00 (6.50, 11.50)	0.9
LV wall thickness (PL), mm	9.00 (7.00, 9.00)	8.00 (6.00, 9.00)	9.00 (7.00, 10.50)	0.12
Global radial strain, CMR (%)	29 (22, 36)	28 (20, 31)	35 (24, 37)	0.13
Global circumferential strain, CMR (%)	-18.0 (-19.8, -14.8)	-17.8 (-18.3, -13.0)	-18.8 (-20.2, -15.3)	0.2
Global longitudinal strain (GLS), CMR (%)	-14.8 (-17.2, -11.6)	-14.0 (-16.7, -11.9)	-15.3 (-17.6, -10.8)	0.6
Abnormal GLS	24 (83%)	16 (89%)	8 (73%)	0.3
1 Median (Q1, Q3); n (%)
2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test

Comparison by immunosupression escalation variable

Characteristic	Overall N = 491	no escalation N = 211	yes escalation N = 281	p-value2
Age at time of sample (years)	75 (67, 80)	72 (62, 79)	76 (68, 80)	0.3
Female sex	23 (47%)	11 (52%)	12 (43%)	0.5
Race				0.14
asian	1 (2.0%)	1 (4.8%)	0 (0%)
black/aa	6 (12%)	4 (19%)	2 (7.1%)
white	42 (86%)	16 (76%)	26 (93%)
Ethnicity				>0.9
hispanic/latinx	1 (2.0%)	0 (0%)	1 (3.6%)
not hispanic/latinx	48 (98%)	21 (100%)	27 (96%)
Death	19 (40%)	5 (24%)	14 (52%)	0.049
Prolonged immunosuppression	29 (63%)	1 (5.6%)	28 (100%)	<0.001
Number of non-HLA positive beads	4.0 (1.0, 12.0)	3.5 (1.0, 8.0)	11.0 (1.0, 14.0)	0.3
Hypertension	46 (94%)	20 (95%)	26 (93%)	>0.9
Hyperlipidemia	39 (80%)	16 (76%)	23 (82%)	0.7
Coronary artery disease	31 (63%)	15 (71%)	16 (57%)	0.3
Diabetes mellitus	12 (24%)	5 (24%)	7 (25%)	>0.9
Heart failure	17 (35%)	5 (24%)	12 (43%)	0.2
LGE burden, CMR (% LV mass)	8 (3, 14)	9 (0, 14)	7 (3, 13)	0.7
LVEF, CMR (%)	59 (47, 64)	53 (41, 60)	62 (57, 64)	0.005
RVEF, CMR (%)	52 (47, 55)	50 (37, 54)	52 (48, 58)	0.2
LV wall thickness (AP), mm	10.00 (8.00, 11.00)	10.00 (8.00, 12.00)	10.00 (8.00, 11.00)	0.6
LV wall thickness (PL), mm	8.00 (7.00, 10.00)	8.00 (7.00, 10.00)	8.00 (7.00, 9.00)	0.8
Global radial strain, CMR (%)	26 (20, 35)	22 (18, 29)	29 (22, 37)	0.038
Global circumferential strain, CMR (%)	-16.0 (-19.6, -13.6)	-15.1 (-18.0, -12.7)	-17.9 (-20.5, -14.7)	0.049
Global longitudinal strain (GLS), CMR (%)	-13.3 (-16.1, -9.6)	-12.1 (-14.9, -8.8)	-13.6 (-17.9, -10.7)	0.2
Abnormal GLS	35 (85%)	17 (94%)	18 (78%)	0.2
1 Median (Q1, Q3); n (%)
2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test

ROC: AT1R (bracket value) predicting death + best threshold (Youden)